VistaGen Therapeutics, Sanwa Kagaku Kenkyusho Co., RainDance Technologies, Becton Dickinson, National Institutes of Health, Galapagos — BioFocus DPI, University College London | GenomeWeb
Sanwa Licenses VistaGen's ES Cell Assays for Diabetes Drug Development
 
Japanese pharmaceutical firm Sanwa Kagaku Kenkyusho has licensed VistaGen Therapeutics’ embryonic stem cell-based assay systems for use in diabetes drug development, VistaGen said this week.
 
Under the terms of the license agreement, Sanwa will use three of VistaGen’s customized beta-islet differentiation assay systems to identify and screen new small-molecule drug candidates to treat type 1 and type 2 diabetes.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.